Canaccord Genuity Raises Natera (NTRA) Price Target to $500
Key Points
- Canaccord Genuity maintained its Buy rating on Natera, Inc. (NasdaqGS: NTRA) on October 19, 2026, raising its price target from $375 to $500.
- Canaccord Genuity's $500 price target implies 23.60% upside from Natera, Inc.'s ($NTRA) current $404.52 share price.
- The diagnostics company recently posted trailing twelve month revenue of $2.71 billion with an EPS of -$1.35, and its next earnings report is scheduled for November 5, 2026.
- Wall Street sentiment remains strong overall, backed by 22 analyst opinions and a consensus recommendation key of strong buy.
Get Natera text alerts
We text you when insiders, Congress, analysts or big funds move on $NTRA.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures
Canaccord Genuity maintained its Buy rating on Natera, Inc. (NasdaqGS: NTRA) on October 19, 2026, while lifting its price target from $375 to $500. The update from the firm arrives as Wall Street analysts continue adjusting their outlooks for the genetic testing and diagnostics provider. Natera closed at $404.27 on the day of the announcement.
NTRA
Natera, Inc.
Canaccord Genuity vs. the S&P 500
Hypothetical returns from Canaccord Genuity's disclosed trades, not real profit or advice. How we model this.
Canaccord Genuity's Call on Natera, Inc.
On October 19, 2026, Canaccord Genuity kept its Buy rating on Natera while raising its target to $500 from the previous level of $375. The firm's forward-looking view joins a series of recent updates from other major financial institutions covering the healthcare company.
Other Institutional Activity in Natera, Inc.
Duquesne Family Office Llc grew its holdings by 122,845 shares, ending with 3,186,306 shares worth about $1.29 billion.
Natera, Inc. Stock Down 0.1%
Natera recently traded around $404.52 as of October 19, 2026. The stock closed at $404.27 on the date of Canaccord's update.
$NTRA price target
Natera, Inc. daily closes and this analyst's $500 target. Not advice.
Recent Earnings
Natera reported trailing twelve month revenue of $2.71 billion alongside trailing twelve month earnings per share of -$1.35. The company's next earnings release is scheduled for November 5, 2026.
Insider Buying and Selling at Natera, Inc.
Insiders have been active with share dispositions ahead of the autumn updates. Solomon Moshkevich sold 18,160 shares valued at $5.92 million on September 2, 2026. Matthew Rabinowitz executed multiple sales, including 50,000 shares for $16.40 million on September 11, 2026, 102,000 shares for $34.80 million on September 15, 2026, and another 50,000 shares for $20.13 million on October 15, 2026, under a planned trading arrangement.
Analysts Set New Price Targets
Barclays maintained an Overweight rating on October 7, 2026, moving its price target from $340 to $475. Morgan Stanley maintained an Overweight rating on October 13, 2026, raising its target from $355 to $435. TD Cowen maintained a Buy rating on October 13, 2026, lifting its target from $340 to $480. JP Morgan maintained an Overweight rating on October 14, 2026, increasing its target from $360 to $460. Overall, the company holds a consensus recommendation key of strong buy from 22 analyst opinions, with a mean price target of $403.89.
About Natera, Inc.
Natera, Inc. is an Austin, Texas-based diagnostics and molecular testing company that creates personalized blood tests for cancer detection, recurrence monitoring, and hereditary screening services. The firm's advanced genomic profiling platforms support oncologists and patients with customized treatment tracking data.
Bottom Line
Investors will look toward Natera's upcoming earnings release on November 5, 2026, for further updates on commercial progress and financial performance.
Related Filing Alerts
Source: Canaccord Genuity's rating change on $NTRA (Oct 19, 2026). Written by software, not financial advice. How we make alerts